ValiRx plc
(the "Company")
Issue of equity
The Company announces that it has issued 56,667 new ordinary shares of 6p each
in the Company ("Ordinary Shares") at 12p per share in respect of services
provided. Application has been made for the new Ordinary Shares to be admitted
to trading on AIM and dealings are expected to commence on 3 December 2007
("Admission"). On Admission the Company will have 31,613,097 Ordinary Shares in
issue.
For further information please contact:
ValiRx plc WH Ireland Limited GTH Communications
Dr Satu Vainikka David Youngman Toby Hall / Jade Mamarbachi
+44 (0) 207 408 5400 +44 (0) 161 832 2174 +44 (0) 20 7153 8039 / 8035
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.